Last reviewed · How we verify
Perjeta + Trastuzumab + Docetaxel
This combination uses two HER2-targeting monoclonal antibodies (Perjeta and Trastuzumab) plus a taxane chemotherapy to block HER2 signaling and inhibit microtubule dynamics in HER2-positive breast cancer cells.
This combination uses two HER2-targeting monoclonal antibodies (Perjeta and Trastuzumab) plus a taxane chemotherapy to block HER2 signaling and inhibit microtubule dynamics in HER2-positive breast cancer cells. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (neoadjuvant/adjuvant setting).
At a glance
| Generic name | Perjeta + Trastuzumab + Docetaxel |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Monoclonal antibody combination + taxane chemotherapy |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Perjeta (pertuzumab) and Trastuzumab (herceptin) are both monoclonal antibodies that target HER2, a growth factor receptor overexpressed in certain breast cancers. Pertuzumab blocks HER2 dimerization while trastuzumab directly binds HER2, together preventing ligand-independent and ligand-dependent signaling. Docetaxel is a taxane chemotherapy that stabilizes microtubules and induces apoptosis, providing synergistic cytotoxic activity.
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive early-stage breast cancer (neoadjuvant/adjuvant setting)
Common side effects
- Neutropenia
- Anemia
- Neuropathy (peripheral)
- Nausea/vomiting
- Fatigue
- Diarrhea
- Cardiac dysfunction (left ventricular ejection fraction decline)
- Infusion reactions
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- ctDNA in HER2+ EBC Neoadjuvant Treatment (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer (PHASE2, PHASE3)
- Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer (PHASE2)
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (PHASE3)
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: